Willy Burgdorfer

Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate

Retrieved on: 
Monday, July 19, 2021
Medical specialties, Lyme disease, Medicine, Microbiology, Borrelia, Valneva SE, Vaccine, Willy Burgdorfer, Subunit vaccine, Lyme disease microbiology

Juan Carlos Jaramillo M.D., Chief Medical Officer of Valneva, said, This recruitment completion represents another important milestone in the development of VLA15.

Key Points: 
  • Juan Carlos Jaramillo M.D., Chief Medical Officer of Valneva, said, This recruitment completion represents another important milestone in the development of VLA15.
  • If successful, this trial could enable the inclusion of a pediatric population in the Phase 3 trial.
  • VLA15 is the only active Lyme disease vaccine candidate in clinical development today, and covers six serotypes that are prevalent in North America and Europe.
  • This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease.

Juniper Advisory Adds Raymond Grady as a Senior Advisor

Retrieved on: 
Thursday, June 10, 2021
Consulting, Hospitals, Health, Professional services, Practice Management, Juniper Advisory, Willy Burgdorfer, Adviser, Stakeholder, Economy, Service companies

Juniper Advisory announced that Raymond Grady has joined the firm as a Senior Advisor.

Key Points: 
  • Juniper Advisory announced that Raymond Grady has joined the firm as a Senior Advisor.
  • Throughout his career, Grady has partnered with community stakeholders, clinical professionals and regulatory agencies overseeing hospital partnership transactions.
  • At Juniper, Grady intends to help clients build quality and diversity into their strategic plans, as well provide practical advice regarding opportunities for business combinations.
  • We are privileged to have him join our team, noted Rex Burgdorfer , Partner at Juniper Advisory.

Ticks Carrying Disease Found to Be Abundant in Beach Areas, Similar to Woodlands, According to New Study

Retrieved on: 
Friday, April 23, 2021
Medical specialties, Lyme disease, Bacterial diseases, Tick-borne diseases, Branches of biology, Microbiology, Neurodegenerative disorders, Spirochaetes, Borrelia, Willy Burgdorfer, Tick, Vector

Now, we have a new imperative to look at the collective risk of all tick-borne pathogens in an area.

Key Points: 
  • Now, we have a new imperative to look at the collective risk of all tick-borne pathogens in an area.
  • "\nThis was the first study to characterize bacteria carried by ticks in the chaparral in beach areas.
  • The most common vector-borne infectious disease in the country, Lyme disease is a potentially disabling infection caused by the Borrelia burgdorferi bacteria.
  • For more information about Lyme disease or to get involved, visit www.bayarealyme.org or call us at 650-530-2439.\n'

Galaxy Diagnostics Launches the Most Sensitive Test Available for Direct Detection of Lyme Disease

Retrieved on: 
Tuesday, November 10, 2020
Lyme disease, Medical specialties, Medicine, Branches of biology, Neuroborreliosis, Borrelia, Willy Burgdorfer, Antibody, Draft:IGeneX, Lyme disease microbiology

This urine-based Lyme antigen test provides the most sensitive direct detection of Borrelia burgdorferi infection at all stages of the disease.

Key Points: 
  • This urine-based Lyme antigen test provides the most sensitive direct detection of Borrelia burgdorferi infection at all stages of the disease.
  • The test provides advantages antibody testing does not, namely:
    The revolutionary test greatly increases the likelihood of Lyme disease confirmation via innovative Nanotrap technology developed by Ceres Nanosciences .
  • Galaxy validation data (unpublished) shows that the Nanotrap Urine Test will often confirm active infection in patients with negative TTT results.
  • Further research is needed to confirm clinical utility for other presentations of Lyme borreliosis, including Lyme arthritis, Lyme carditis, and neuroborreliosis.

New Opinion Article Published in Scientific Journal Highlights Exceptional Lyme Research From Global Lyme Alliance-Funded Investigator

Retrieved on: 
Wednesday, October 14, 2020
Borrelia, Medical specialties, Medicine, Spirochaetes, Infectious diseases, Lyme disease, RTT, Willy Burgdorfer, Tick-borne disease, Jorge Benach, Draft:IGeneX

STAMFORD, Conn., Oct. 14, 2020 /PRNewswire-PRWeb/ -- Global Lyme Alliance (GLA) is excited to announce that the scientific journal, Frontiers in Cellular and Infection Microbiology has accepted and published an article written by Global Lyme Alliance's Chief Scientific Officer, Timothy Sellati, Ph.D., titled, Mechanisms of Dysregulated Antibody Response in Lyme Disease.

Key Points: 
  • STAMFORD, Conn., Oct. 14, 2020 /PRNewswire-PRWeb/ -- Global Lyme Alliance (GLA) is excited to announce that the scientific journal, Frontiers in Cellular and Infection Microbiology has accepted and published an article written by Global Lyme Alliance's Chief Scientific Officer, Timothy Sellati, Ph.D., titled, Mechanisms of Dysregulated Antibody Response in Lyme Disease.
  • The article represents Global Lyme Alliance's unwavering commitment to identify and fund the most innovative and promising Lyme disease research.
  • The article also highlights Dr. Baumgarth's important research on how Borrelia burgdorferi infection in mice promotes changes to cause immune dysfunction.
  • Global Lyme Alliance is the leading 501(c)(3) organization dedicated to conquering Lyme and other tick-borne diseases through research, education, awareness, and patient services.

Valneva Announces Positive Initial Results for Phase 2 Study of Lyme Disease Vaccine Candidate

Retrieved on: 
Wednesday, July 22, 2020
Medical specialties, Infectious diseases, Medicine, Lyme disease, Bacterial diseases, Neurodegenerative disorders, Tick-borne diseases, Borrelia, Valneva SE, Willy Burgdorfer, Vaccine

Saint-Herblain (France), July 22, 2020 Valneva SE (Valneva), a specialty vaccine company focused on prevention of diseases with major unmet needs, today announced positive initial results for its first Phase 2 study (VLA15-201) of Lyme disease vaccine candidate VLA15.

Key Points: 
  • Saint-Herblain (France), July 22, 2020 Valneva SE (Valneva), a specialty vaccine company focused on prevention of diseases with major unmet needs, today announced positive initial results for its first Phase 2 study (VLA15-201) of Lyme disease vaccine candidate VLA15.
  • The immunological response in older adults, one of the main target groups for a Lyme vaccine, is particularly encouraging.
  • Valneva expects to report top-line results for the second Phase 2 study, VLA15-202, in a few months.
  • Study centers for this study were located in areas where Lyme disease is endemic; subjects with a cleared past infection with Borrelia burgdorferi, the bacteria that cause Lyme disease, were also enrolled.

HelixBind Awarded $3MM Grant from NIH for New Rapid Test for the Early Detection of Lyme Disease

Retrieved on: 
Thursday, July 16, 2020
Lyme disease, Infectious diseases, Medical specialties, Medicine, Bacterial diseases, Tick-borne diseases, Spirochaetes, Borrelia burgdorferi, Borrelia, Willy Burgdorfer, Lyme disease microbiology, Southern tick-associated rash illness

Lyme Disease, caused by the tick-borne bacteria Borrelia burgdorferi, is a serious health concern in North America with approximately 300,000 cases annually.

Key Points: 
  • Lyme Disease, caused by the tick-borne bacteria Borrelia burgdorferi, is a serious health concern in North America with approximately 300,000 cases annually.
  • If diagnosed early and treated with appropriate antibiotics, recovery is generally rapid and complete.
  • Unfortunately, definitive diagnosis of Lyme Disease is difficult today as early symptoms are often non-descript including headaches, muscle or joint pain, and fevers.
  • This new grant from the NIH will help us demonstrate whether the improved sensitivity of our test can improve diagnosis and help those afflicted with Lyme Disease.

New Study Shows Nearly One-Third of Lyme Disease Test Results are Inaccurate for Patients with Lyme Disease Rash

Retrieved on: 
Wednesday, February 26, 2020
Lyme disease, Infectious diseases, Medical specialties, Medicine, Bacterial diseases, Tick-borne diseases, Neurodegenerative disorders, Spirochaetes, Borrelia burgdorferi, Borrelia, Willy Burgdorfer, Lyme disease microbiology

These samples are part of the Lyme Disease Biobank (LDB), which was founded to catalyze new research in the understanding, diagnosis and treatment of Lyme disease and other tick-borne infections.

Key Points: 
  • These samples are part of the Lyme Disease Biobank (LDB), which was founded to catalyze new research in the understanding, diagnosis and treatment of Lyme disease and other tick-borne infections.
  • Samples that were laboratory confirmed for Lyme disease (N=82) were more likely to be enrolled with a Lyme rash (83%) and more likely to present with a Lyme rash greater than 5 cm (74%).
  • "This study highlights the limitations of available tools for all healthcare providers whose patients may be infected with Borrelia burgdorferi, the bacteria that causes Lyme disease.
  • The Lyme Disease Biobank (LDB), a program of the Bay Area Lyme Foundation, is a non-profit organization working to accelerate research of Lyme disease and other tick-borne infections.

QIAGEN and DiaSorin collaborate on novel QuantiFERON-based test with breakthrough potential for earlier detection of Lyme disease

Retrieved on: 
Wednesday, June 5, 2019
Health, Biotechnology, Medical devices, Other Health, Medical Supplies, General Health, Medical specialties, Infectious diseases, Medicine, Lyme disease, Borrelia, Bacterial diseases, Neurodegenerative disorders, Tick-borne diseases, QuantiFERON, Willy Burgdorfer, Lyme disease microbiology, Tick

The companies plan multi-site clinical validations during the 2020 Lyme disease season, with regulatory submissions expected at the end of the same year in the United States and Europe.

Key Points: 
  • The companies plan multi-site clinical validations during the 2020 Lyme disease season, with regulatory submissions expected at the end of the same year in the United States and Europe.
  • Lyme disease, also called borreliosis, is an infection caused by the Borrelia burgdorferi bacterium, which is transmitted to humans through the bite of blacklegged ticks.
  • Approximately 30,000 confirmed cases of Lyme disease per year are reported to the U.S. Centers for Disease Control (CDC), but the CDC notes that recent estimates suggest about 300,000 individuals may get Lyme disease annually in the U.S.
  • T cell response, as measured through the QuantiFERON technology, precedes B cell response and has the potential to provide significantly better sensitivity and earlier detection of the infection.

Charles E. Holman Morgellons Disease Foundation Announces Study Showing Bacterial Biofilms are Implicated in Morgellons Disease.

Retrieved on: 
Tuesday, May 21, 2019
Medical specialties, Branches of biology, Microbiology, Bacteriology, Lyme disease, Delusional disorders, Delusions, Morgellons, Borrelia burgdorferi, Biofilm, Willy Burgdorfer, Bacteria

AUSTIN, Texas, May 21, 2019 /PRNewswire-PRWeb/ -- A new study entitled "Mixed Borrelia burgdorferi and Helicobacter pylori Biofilms in Morgellons Disease Dermatological Specimens" revealed that mixed bacterial biofilms are present within Morgellons disease skin specimens.

Key Points: 
  • AUSTIN, Texas, May 21, 2019 /PRNewswire-PRWeb/ -- A new study entitled "Mixed Borrelia burgdorferi and Helicobacter pylori Biofilms in Morgellons Disease Dermatological Specimens" revealed that mixed bacterial biofilms are present within Morgellons disease skin specimens.
  • "This paper provides further evidence for an infectious origin of Morgellons disease," says Cindy Casey-Holman, director of the Charles E. Holman Morgellons Disease Foundation (CEHMDF) of Austin, TX, which is dedicated to finding a cause and cure for the skin disease.
  • The Charles E. Holman Morgellons Disease Foundation, based in Austin, TX, is a 501(c) (3) nonprofit organization committed to advocacy and philanthropy in the battle against Morgellons disease.
  • Director Cindy Casey-Holman, RN, leads the foundation named for her husband Charles E. Holman, a pioneer in the fight against Morgellons disease.